Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 14/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminodiphenylmethane SCHEMBL4551064 | 0.78 | F2R (0.47) | F2RF2ITGB1ITGA4ITGB7 | |
| Aminodiphenylmethane SCHEMBL4551156 | 0.73 | F2R (0.52) | F2RF2 | |
| SCHEMBL4316805 | 0.72 | GAA (0.46) | — | |
| SCHEMBL12340133 | 0.71 | F2R (0.56) | F2RF2 | |
| SCHEMBL13968276 | 0.69 | F2R (0.53) | F2RF2 | |
| SCHEMBL12340158 | 0.67 | F2R (0.65) | F2RF2 | |
| SCHEMBL3386016 | 0.67 | CACNB4 (0.46) | F2RF2 | |
| SCHEMBL12340126 | 0.67 | F2R (0.63) | F2RF2 | |
| SCHEMBL12340155 | 0.64 | F2R (0.67) | F2RF2 | |
| SCHEMBL12340129 | 0.64 | F2R (0.65) | F2RF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1806355-A1 | PROCESS FOR PRODUCTION OF (1,3-DISUBSTITUTED INDOLYL)- UREA DERIVATIVES, INTERMEDIATES THEREFOR, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATES | Kowa Company Ltd. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012263-A1 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates | WEE1, WASF2, IDO1 | F2R 2248/4885F2 475/4885ITGB1 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.